Zevalin/Rituxan Has 80% Response Rate In Non-Hodgkin's Lymphoma Patients
Idec's mouse monoclonal antibody Zevalin in combination with the firm's Rituxan produced an 80% overall response rate in patients with relapsed B-cell non-Hodgkin's lymphoma in an interim analysis of Phase III data presented in a poster May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.
You may also be interested in...
First-line use of Genentech's Herceptin (trastuzumab) is increasing with the growing number of breast cancer patients who are being tested for overexpression of the HER2 protein.
New NDA filing for the iodine I 131 tositumomab product is no longer expected by mid-October, CEO Michael Bigham told analysts Sept. 28. The Aug. 27 "refuse-to-file" letter from FDA required Coulter to reformat selected data sets, reorganize certain analyses and provide archival images. Bigham said a meeting the company requested with FDA will not take place until mid-October, delaying the resubmission. Co-marketing partner SmithKline Beecham has indicated that it is helping Coulter with the submission (1"The Pink Sheet" Sept. 27, p. 22)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011